Drug Trial Radar · NCT03520478
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
654
Actual
Start
May 30, 2018
Primary completion
Apr 30, 2023
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.
Conditions
- Prostate Cancer
- Hormone-Dependent Prostate Cancer
Interventions
SHR3680Drug
Tablet. Specifications of 80 mg; orally, once a day
BicalutamideDrug
Tablet. Specifications of 50 mg; orally, once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- rPFSTime frame: Approximately 70 months
- OSTime frame: Approximately 70 months
Locations
67 sites in 4 countries. Site status is shown where the registry gives one.
Complex oncological center - Bourgas
Burgas, Bulgaria
UMHAT 'Deva Maria'. EOOD
Burgas, Bulgaria
MHAT - Dobrich. AD
Dobrich, Bulgaria
MHAT 'Dr. Tota Venkova'. AD
Gabrovo, Bulgaria
Complex Oncological Center - Plovdiv. EOOD
Plovdiv, Bulgaria
MHAT 'Central Onco Hospital'. OOD
Plovdiv, Bulgaria
Acibadem City Clinic Tokuda Hospital Ead
Sofia, Bulgaria
Affiliated Hospital of Hebei University
Baoding, China
Beijing Cancer Hospital
Beijing, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Peking Union Medical College Hospital
Beijing, China
The third hospital of Peking University
Beijing, China
Tumor Hospital of the Chinese Academy of Medical Sciences
Beijing, China
China Japan Friendship Hospital of Jilin University
Changchun, China
The first hospital of Jilin University
Changchun, China
Hunan Cancer Hospital
Changsha, China
West China Hospital of Sichuan University
Chengdu, China
Army characteristic medical center of the Chinese people's Liberation Army
Chongqing, China
Chongqing Cancer Hospital
Chongqing, China
The First Affiliated Hospital of Army Medical University
Chongqing, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Sun Yat-Sen hospital of Sun Yat-Sen University
Guangzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
The First Affiliated Hospital of Zhejiang University Medicine college
Hangzhou, China
The Second affiliated hospital of zhejiang university medical college
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Zhejiang Province People's Hospital
Hangzhou, China
Anhui Provincial Hospital
Hefei, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Qilu Hospital of Shandong University
Jinan, China
Yunnan Provincial Cancer Hospital
Kunming, China
The second hospital of Lanzhou University
Lanzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Gulou Hospital Affiliated to Medical College of Nanjing University
Nanjing, China
Jiangsu Provincial Cancer Hospital
Nanjing, China
Jiangsu Provincial People's Hospital
Nanjing, China
Huadong Hospital of Fudan University
Shanghai, China
Ruijin Hospital
Shanghai, China
Shanghai General Hospital
Shanghai, China
The Cancer Hospital of Fudan University
Shanghai, China
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.